Clinical Trial

Epcoritamab in Previously Treated WM

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is being done to determine if epcoritamab can be used to treat participants with previously treated Waldenstrom Macroglobulinemia (WM). The names of the study drug involved in this study is: -Epcoritamab (a type of antibody)
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-07-15; most recent amendment 2026-03-12.
Status change: Not Yet Recruiting → Recruiting 2024-12-16
Trial Details
NCT Number NCT06510491
Lead Sponsor Gottfried von Keudell, MD PhD
Collaborators: Genmab
Conditions Waldenstrom Macroglobulinemia, B-Cell Lymphoproliferative Disorder
Enrollment 20 participants
Start Date 2024-12-06
Primary Completion 2027-04-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-13